STAG2 mutation
|
AML
|
STAG2 mutation
|
AML
|
talazoparib Sensitive: C2 – Inclusion Criteria
|
talazoparib Sensitive: C2 – Inclusion Criteria
|
STAG2 mutation
|
AML
|
STAG2 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
STAG2 mutation
|
AML
|
STAG2 mutation
|
AML
|
LY3009120 Resistant: C3 – Early Trials
|
LY3009120 Resistant: C3 – Early Trials
|
STAG2 mutation
|
CRC
|
STAG2 mutation
|
CRC
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
STAG2 mutation
|
GBM
|
STAG2 mutation
|
GBM
|
olaparib Sensitive: D – Preclinical
|
olaparib Sensitive: D – Preclinical
|